Fibroblast Growth Factor 23 and Cardiovascular Mortality after Kidney Transplantation

被引:98
作者
Baia, Leandro C. [1 ,2 ]
Humalda, Jelmer K. [1 ]
Vervloet, Marc G. [3 ]
Navis, Gerjan [1 ]
Bakker, Stephan J. L. [1 ]
de Borst, Martin H. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, NL-9700 RB Groningen, Netherlands
[2] Univ Fed Sao Paulo, Dept Nephrol, Sao Paulo, Brazil
[3] Vrije Univ Amsterdam Med Ctr, Dept Nephrol, Amsterdam, Netherlands
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2013年 / 8卷 / 11期
关键词
LEFT-VENTRICULAR HYPERTROPHY; METABOLIC SYNDROME; DISEASE; RISK; EVENTS; SERUM; FGF23; INCREASES; PEPTIDE; FGF-23;
D O I
10.2215/CJN.01880213
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
Background and objectivesCirculating fibroblast growth factor 23 (FGF23) is associated with adverse cardiovascular outcomes in CKD. Whether FGF23 predicts cardiovascular mortality after kidney transplantation, independent of measures of mineral metabolism and cardiovascular risk factors, is unknown.Design, setting, participants, & measurementsThe association between plasma C-terminal FGF23 and cardiovascular mortality was analyzed in a single-center prospective cohort of 593 stable kidney transplant recipients (mean age SD, 5212 years; 54% male; estimated GFR, 47 +/- 16 ml/min per 1.73 m(2)), at a median of 6.1 (interquartile range, 2.7-11.7) years after transplantation. Multivariate Cox regression models were built, adjusting for measures of renal function and mineral metabolism; Framingham risk factors; the left ventricular wall strain markers midregional fragment of pro-A-type natriuretic peptide (MR-proANP) and N-terminal-pro brain natriuretic peptide (NT-proBNP); and copeptin, the stable C-terminal portion of the precursor of vasopressin.ResultsIn multivariate linear regression analysis, MR-proANP (=0.20, P<0.001), NT-proBNP (=0.18, P<0.001), and copeptin (=0.26, P<0.001) were independently associated with FGF23. During follow-up for 7.0 (interquartile range, 6.2-7.5) years, 128 patients (22%) died, of whom 66 (11%) died due to cardiovascular disease; 54 (9%) had graft failure. FGF23 was associated with an higher risk of cardiovascular mortality in a fully adjusted multivariate Cox regression model (hazard ratio [HR], 1.88 [95% confidence interval (CI), 1.11 to 3.19]; P=0.02). FGF23 was also independently associated with all-cause mortality (full model HR, 1.86 [95% CI, 1.27 to 2.73]; P=0.001). Net reclassification improved for both cardiovascular mortality (HR, 0.07 [95% CI, 0.01 to 0.14]; P<0.05) and all-cause mortality (HR, 0.11 [95% CI, 0.05 to 0.18]; P<0.001).ConclusionsPlasma FGF23 is independently associated with cardiovascular and all-cause mortality after kidney transplantation. The association remained significant after adjustment for measures of mineral metabolism and cardiovascular risk factors.
引用
收藏
页码:1968 / 1978
页数:11
相关论文
共 37 条
[1]
Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study [J].
Abbasi, A. ;
Corpeleijn, E. ;
Meijer, E. ;
Postmus, D. ;
Gansevoort, R. T. ;
Gans, R. O. B. ;
Struck, J. ;
Hillege, H. L. ;
Stolk, R. P. ;
Navis, G. ;
Bakker, S. J. L. .
DIABETOLOGIA, 2012, 55 (07) :1963-1970
[3]
Serum FGF23 and Risk of Cardiovascular Events in Relation to Mineral Metabolism and Cardiovascular Pathology [J].
Arnlov, Johan ;
Carlsson, Axel C. ;
Sundstrom, Johan ;
Ingelsson, Erik ;
Larsson, Anders ;
Lind, Lars ;
Larsson, Tobias E. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 8 (05) :781-786
[4]
Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community [J].
Arnlov, Johan ;
Carlsson, Axel C. ;
Sundstrom, Johan ;
Ingelsson, Erik ;
Larsson, Anders ;
Lind, Lars ;
Larsson, Tobias E. .
KIDNEY INTERNATIONAL, 2013, 83 (01) :160-166
[5]
THE EVOLVING CONCEPT OF THE HEALTHY WORKER SURVIVOR EFFECT [J].
ARRIGHI, HM ;
HERTZPICCIOTTO, I .
EPIDEMIOLOGY, 1994, 5 (02) :189-196
[6]
Cross Talk Between the Renin-Angiotensin-Aldosterone System and Vitamin D-FGF-23-klotho in Chronic Kidney Disease [J].
de Borst, Martin H. ;
Vervloet, Marc G. ;
ter Wee, Piet M. ;
Navis, Gerjan .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (09) :1603-1609
[7]
Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally [J].
de Vries, APJ ;
Bakker, SJL ;
van Son, WJ ;
van der Heide, JJH ;
Ploeg, RJ ;
The, HT ;
de Jong, PE ;
Gans, ROB .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (10) :1675-1683
[8]
Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease [J].
Doorenbos, Carolina R. C. ;
de Cuba, Milton M. ;
Vogt, Liffert ;
Kema, Ido P. ;
van den Born, Jacob ;
Gans, Reinold O. B. ;
Navis, Gerjan ;
de Borst, Martin H. .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2012, 128 (1-2) :56-61
[9]
FGF23 induces left ventricular hypertrophy [J].
Faul, Christian ;
Amaral, Ansel P. ;
Oskouei, Behzad ;
Hu, Ming-Chang ;
Sloan, Alexis ;
Isakova, Tamara ;
Gutierrez, Orlando M. ;
Aguillon-Prada, Robier ;
Lincoln, Joy ;
Hare, Joshua M. ;
Mundel, Peter ;
Morales, Azorides ;
Scialla, Julia ;
Fischer, Michael ;
Soliman, Elsayed Z. ;
Chen, Jing ;
Go, Alan S. ;
Rosas, Sylvia E. ;
Nessel, Lisa ;
Townsend, Raymond R. ;
Feldman, Harold I. ;
Sutton, Martin St. John ;
Ojo, Akinlolu ;
Gadegbeku, Crystal ;
Di Marco, Giovana Seno ;
Reuter, Stefan ;
Kentrup, Dominik ;
Tiemann, Klaus ;
Brand, Marcus ;
Hill, Joseph A. ;
Moe, Orson W. ;
Kuro-o, Makoto ;
Kusek, John W. ;
Keane, Martin G. ;
Wolf, Myles .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (11) :4393-4408
[10]
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The mild to moderate kidney disease (MMKD) study [J].
Fliser, Danilo ;
Kollerits, Barbara ;
Neyer, Ulrich ;
Ankerst, Donna P. ;
Lhotta, Karl ;
Lingenhel, Arno ;
Ritz, Eberhard ;
Kronenberg, Florian .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (09) :2600-2608